Table 1.
Demographic and clinical characteristics of the 89 children with a genotype
| Characteristic | Outcome |
|---|---|
|
Gender, male, n (%) |
53 (59.6) |
|
At ART initiation | |
|
Age, years, median (IQR) |
7 (3.7-9.6) |
| Number of children per age group n(%) |
|
| 0-3 years |
17 (23) |
| 4-9 years |
37 (50) |
| 10-15 years |
20 (27) |
|
Viral load, log10 copies/ml, median (IQR) |
4.0 (3.7-4.7) |
|
CD4+ cell count, cells/μl, median (IQR) |
286 (112–560) |
| By Age category: |
|
| 0 - 2 yrs (n = 3) |
817 (31–1564) |
| >2 – 5 yrs (n = 29) |
469 (194–619) |
| >5 yrs (n = 38) |
200 (69–363) |
|
ART regimen,n (%) |
|
| d4T/3TC/EFV |
64 (71.9) |
| d4T/3TC/LPVr |
12 (13.5) |
| ABC/3TC/EFV |
8 (8.9) |
| ABC/3TC/LPVr |
4 (4.5) |
| AZT/3TC/EFV |
1 (1.1) |
|
At genotyping | |
|
Age, years, median (IQR) |
10.2 (7.7 – 12.9) |
| Number of children per age group n(%) |
|
| 0-3 years |
4 (4.5) |
| 4-9 years |
38 (42.7) |
| 10-15 years |
47 (52.8) |
|
Viral load prior to genotyping*, log10 copies/ml, median (IQR) |
4.2 (3.8-4.8) |
|
CD4+ cell count prior to genotyping*, cells/μl, |
460 (228–769) |
| median (IQR) |
|
| By Age category: |
2339 (1621–2538) |
| 0 - 2 yrs (n = 4 ) |
685 (442–956) |
| 2 – 5 yrs (n = 37) |
295 (147–564) |
| >5 yrs (n = 47) |
|
|
ART regimen at time of genotyping,n (%) |
|
| d4T/3TC/EFV |
58 (65.2) |
| d4T/3TC/LPVr |
8 (8.9) |
| ABC/3TC/EFV |
14 (15.7) |
| ABC/3TC/LPVr |
8 (8.9) |
| AZT/3TC/EFV |
1 (1.1) |
|
Duration of ART, years, median (IQR) |
3.3 (2.5-4.4) |
|
Duration of ART failure
†
, years, median (IQR) |
1.8 (0.8-2.4) |
|
Time between last viral load and genotype, months, median (IQR) |
3.1 (1.4-7.0) |
| History of ART substitution # , yes, n (%) | 12 (13.5) |
Key:
d4T, stavudine; 3TC, lamivudine; EFV, efavirenz; LPVr, lopinavir/ritonavir; ABC, abacavir; AZT, zidovudine; ART, antiretroviral therapy; IQR, interquartile range.
*Last measurements recorded prior to date of genotype.
†Duration of antiretroviral failure was estimated from the date of the first viral load >1000 copies/ml to date of genotype, unless there was a viral load <50 copies/ml in-between, in which case the time was estimated from the next viral load >1,000 copies/ml. If there was no viral load ≤1,000 copies/ml then time was calculated from date of ART initiation.
#Substitutions included changes of single drugs due to toxicity or guideline changes.